Therapeutic Options for Coronavirus Disease 2019 (COVID-19)-Modulation of Type I Interferon Response as a Promising Strategy?

被引：6
作者：
Mary, Aurelien [1 ,2 ]
Henaut, Lucie [2 ]
Schmit, Jean-Luc [3 ,4 ]
Lanoix, Jean-Philippe [3 ,4 ]
Brazier, Michel [2 ,5 ]
机构：
[1] Amiens Picardie Univ Hosp, Clin Crit Care Pharm Dept, Amiens, France
[2] Univ Picardie Jules Verne, CURS, MP3CV, UR UPJV 7517, Amiens, France
[3] Amiens Picardie Univ Hosp, Infect Dis Dept, Amiens, France
[4] Univ Picardie Jules Verne, CURS, AGIR UR UPJV 4294, Amiens, France
[5] Amiens Picardie Univ Hosp, Dept Biochem, Amiens, France
来源：
FRONTIERS IN PUBLIC HEALTH | 2020年 / 8卷
关键词：
COVID-19; SARS-CoV-2; type I interferon; azithromycin; hydroxychloroquine; HEPATITIS-C; AZITHROMYCIN; INFECTION; CELLS; RIBAVIRIN; COVID-19;
D O I：
10.3389/fpubh.2020.00185
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
[No abstract available]
引用
收藏
页数：4
相关论文
共 30 条
  • [1] [Anonymous], 2020, DIAGN TREATM PROT NO
  • [2] [Anonymous], AFRICAN AM POPULATIO
  • [3] [Anonymous], 2018, J Antivir Antiretrovir, DOI DOI 10.4172/1948-5964.1000173
  • [4] Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses A Randomized Clinical Trial
    Bacharier, Leonard B.
    Guilbert, Theresa W.
    Mauger, David T.
    Boehmer, Susan
    Beigelman, Avraham
    Fitzpatrick, Anne M.
    Jackson, Daniel J.
    Baxi, Sachin N.
    Benson, Mindy
    Burnham, Carey-Ann D.
    Cabana, Michael
    Castro, Mario
    Chmiel, James F.
    Covar, Ronina
    Daines, Michael
    Gaffin, Jonathan M.
    Gentile, Deborah Ann
    Holguin, Fernando
    Israel, Elliot
    Kelly, H. William
    Lazarus, Stephen C.
    Lemanske, Robert F., Jr.
    Ly, Ngoc
    Meade, Kelley
    Morgan, Wayne
    Moy, James
    Olin, Tod
    Peters, Stephen P.
    Phipatanakul, Wanda
    Pongracic, Jacqueline A.
    Raissy, Hengameh H.
    Ross, Kristie
    Sheehan, William J.
    Sorkness, Christine
    Szefler, Stanley J.
    Teague, W. Gerald
    Thyne, Shannon
    Martinez, Fernando D.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (19): : 2034 - 2044
  • [5] Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
  • [6] Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
  • [7] Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia
    Cooper, Curtis L.
    Al-Bedwawi, Saif
    Lee, Craig
    Garber, Gary
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 42 (12) : 1674 - 1678
  • [8] Type I interferons in bacterial infections: taming of myeloid cells and possible implications for autoimmunity
    Eshleman, Emily M.
    Lenz, Laurel L.
    [J]. FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [9] Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
    Gao, Jianjun
    Tian, Zhenxue
    Yang, Xu
    [J]. BIOSCIENCE TRENDS, 2020, 14 (01) : 72 - 73
  • [10] Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
    Gautret, Philippe
    Lagier, Jean-Christophe
    Parola, Philippe
    Van Thuan Hoang
    Meddeb, Line
    Mailhe, Morgane
    Doudier, Barbara
    Courjon, Johan
    Giordanengo, Valerie
    Vieira, Vera Esteves
    Dupont, Herve Tissot
    Honore, Stephane
    Colson, Philippe
    Chabriere, Eric
    La Scola, Bernard
    Rolain, Jean-Marc
    Brouqui, Philippe
    Raoult, Didier
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (01)
123